Document is current
Any future updates will be listed below
-
Authors
Wu, Sui-Yi
Zhu, Yuan-Yuan
Sun, Jia-Lei https://orcid.org/0000-0002-4021-5079
Wang, Chun-Yan
Wang, Yu-Lei https://orcid.org/0000-0002-9057-9786
Nie, Yan-Yan
Song, Fei
Huang, Xun
Chen, Zhong
He, Tian
Shen, Li-An
Xu, Yang
Huang, Cheng
Qiu, Shuang-Jian https://orcid.org/0000-0002-2659-472X
Zhou, Jian https://orcid.org/0000-0002-2118-1117
Zhu, Andrew X.
Fan, Jia https://orcid.org/0000-0001-5158-629X
Zhu, Di https://orcid.org/0000-0003-4622-4600
Hu, Bo
Yang, Xin-Rong https://orcid.org/0000-0002-2716-9338
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82341027)
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 28 October 2025
First Online: 17 November 2025
Competing interests
: A.X.Z. received consulting fees from Bayer, Eisai, Eli Lilly, Exelixis, F. Hoffmann–La Roche, Merck, Gilead, Sanofi Aventis, and Sirtex. The other authors (S.Y.W., Y.Y.Z., J.L.S., C.Y.W., Y.L.W., Y.Y.N., F.S., X.H., Z.C., T.H., L.A.S., Y.X., C.H., S.J.Q., J.Z., J.F., D.Z., B.H., and X.R.Y.) declare no competing financial or non-financial interests.
